GeoVax Labs’ (GOVX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $18.00 price objective on the stock.

Several other research analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a report on Friday, November 15th. Alliance Global Partners started coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Stock Performance

NASDAQ GOVX traded up $0.01 on Wednesday, reaching $2.25. 219,437 shares of the stock traded hands, compared to its average volume of 2,357,253. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18. The firm’s fifty day simple moving average is $2.35 and its 200 day simple moving average is $2.75.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same quarter last year, the firm posted ($4.80) earnings per share. Research analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.